Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

1630GCC: A Pilot Study of Zydelig in Patients With B-cell Malignancies as Post-Autologous Transplant Remission Maintenance

NCT03133221 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT03133221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03133221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
1630GCC: A Pilot Study of Zydelig in Patients With B-cell Malignancies as Post-Autologous Transplant Remission Maintenance
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Completed
Start date
October 23, 2017
Completion date
September 29, 2024
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, follicular lymphoma, indolent lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, non hodgkin lymphoma, small lymphocytic lymphoma, transformed lymphoma, waldenstrom macroglobulinemia